

1 **Fecal bile acid profiles predict recurrence in patients with primary *Clostridioides difficile***
2 **infection**

3 Benjamin H. Mullish^{1,2*}, Laura Martinez-Gili^{1,3*}, Elena Chekmeneva^{4,5}, Gonçalo D. S.
4 Correia^{4,5}, Matthew R. Lewis^{4,5}, Verena Horneffer-Van Der Sluis^{4,5,6}, Julie A. K. McDonald⁷,
5 Alexandros Pechlivanis^{5,8,9}, Julian R. F. Walters^{1,2}, Emma L McClure¹⁰, Julian R. Marchesi¹,
6 Jessica R. Allegretti^{10,11f}

7
8 *Affiliations:*

9 ¹Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction,
10 Faculty of Medicine, St Mary's Hospital Campus, Imperial College London, London, United
11 Kingdom

12 ²Departments of Gastroenterology and Hepatology, St Mary's Hospital, Imperial College
13 Healthcare NHS Trust, Paddington, London, UK

14 ³Section of Bioinformatics, Division of Systems Medicine, Department of Metabolism,
15 Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United
16 Kingdom

17 ⁴National Phenome Centre, Department of Metabolism, Digestion and Reproduction,
18 Faculty of Medicine, IRDB Building, Hammersmith House Campus, Imperial College London,
19 London, United Kingdom

20 ⁵Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of
21 Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom

22 ⁶Department for Diagnostics, Institute for Clinical Chemistry and Laboratory Medicine,
23 University Hospital Hamburg-Eppendorf, Hamburg, Germany

24 ⁷MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, UK

25 ⁸Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of
26 Thessaloniki, Thessaloniki, Greece

27 ⁹Biomic_Auth, Bioanalysis and Omics Laboratory, Center for Interdisciplinary Research and
28 Innovation (CIRI-AUTH), Thessaloniki, Greece

Main Manuscript

29 ¹⁰Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital,
30 Boston, Massachusetts, USA

31 ¹¹Harvard Medical School, Boston, Massachusetts, USA

32

33 *Joint first authors

34 [†]Corresponding author

35

36 **Postal address:** Dr Jessica R Allegretti
37 Division of Gastroenterology, Hepatology and Endoscopy
38 Brigham and Women's Hospital
39 850 Boylston Street, Suite 201
40 Chestnut Hill
41 MA 02467
42 USA

43 **Email:** jallegretti@bwh.harvard.edu

44 **Telephone:** +001-617-732-6389

45 **Fax:** +001-617-732-9198

46

47 **Word count:** 5042

48

49 **Keywords:** metabolomics; bile acids; *Clostridioides difficile* infection

50

51 **Acknowledgements:** Nil.

52

53 **Disclosures:** BHM has received consultancy fees from Finch Therapeutics Group
54 and Ferring Pharmaceuticals, outside of the submitted work. JRFW
55 has received consultancy fees from GE Healthcare, Intercept
56 Pharmaceuticals, and Novome Biotechnologies outside the submitted
57 work. JRM has received consultancy fees from EnteroBiotix Ltd.,
58 outside of the submitted work. JRA has consulted for Finch

Main Manuscript

59 Therapeutics Group, Seres, Pfizer, Janssen, Bristol Myer Squibb,
60 Artugen, Iterative Scopes, Lilly, Merck and Abbvie, and has research
61 support from Merck and Pfizer.

62

63 **Funding:** The clinical studies were funded by a Junior Faculty Development
64 Award from the American College of Gastroenterology for JRA.
65 Metabolomics studies were performed at the MRC-NIHR National
66 Phenome Centre at Imperial College London; this centre receives
67 financial support from the Medical Research Council (MRC) and
68 National Institute of Health Research (NIHR) (grant number
69 MC_PC_12025). BHM is the recipient of an NIHR Academic Clinical
70 Lectureship (CL-2019-21-002) and was formerly in receipt of a MRC
71 Clinical Research Training Fellowship (MR/R000875/1). The Division of
72 Digestive Diseases and MRC-NIHR National Phenome Centre at
73 Imperial College London receive financial and infrastructure support
74 from the NIHR Imperial Biomedical Research Centre (BRC) based at
75 Imperial College Healthcare NHS Trust and Imperial College London.

76

77 1. **Abstract:**

78 **Background:** Factors that influence recurrence risk in primary *Clostridioides difficile*
79 infection (CDI) are poorly understood, and tools to predict recurrence are lacking.
80 Perturbations in microbial-derived bile acids (BAs) contribute to CDI pathogenesis and may
81 be relevant to primary disease prognosis.

82 **Aims:** To define stool bile acid profiles and microbial bile-metabolising functionality in
83 primary CDI patients, and explore signatures predicting recurrence.

84 **Methods:** Weekly stool samples were collected from primary CDI patients from the last day
85 of anti-CDI therapy until recurrence, or through eight weeks post-completion otherwise.
86 Ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) was used to
87 profile bile acids, and bacterial bile salt hydrolase (BSH) activity was measured to determine
88 primary BA deconjugation capacity. Multivariate and univariate models were used to define
89 differential BA trajectories in recurrers *versus* non-recurrers, and assess fecal bile acids as
90 predictive markers for recurrence.

91 **Results:** Twenty (36%) out of 56 patients (median age 57, 64% male) recurred, with 80% of
92 recurrence occurring within the first nine days post-antibiotic treatment. Principal
93 component analysis (PCA) of stool bile acid profiles demonstrated clustering of samples by
94 recurrence status and post-treatment time point. Longitudinal fecal bile acid trajectories in
95 non-recurrers showed a recovery of secondary bile acids and their derivatives in non-
96 recurring patients that was not observed in recurrers. BSH activity increased over time
97 amongst patients who did not relapse ($\beta = 0.056$; likelihood ratio test $p = 0.018$). A joint
98 longitudinal-survival model identified five stool bile acids with AUROC > 0.73 for prediction
99 of recurrence within nine days post-CDI treatment.

100 **Conclusions:** Gut bile acid metabolism dynamics differ in primary CDI patients between
101 those who develop recurrence versus those who do not. Individual bile acids show promise
102 in primary CDI patients as potential novel biomarkers to predict CDI recurrence.

103

104

105 **2. Introduction:**

106 *Clostridioides difficile* infection (CDI) continues to present a considerable global disease
107 burden, with an estimated annual incidence of 462,100 cases in the USA alone on latest
108 assessment, and this trend is expected to increase as antimicrobial resistance is predicted to
109 grow worldwide [1]. While a growing proportion of cases appear to be community-acquired
110 [2], CDI remains the major cause of hospital-acquired gastrointestinal infection [3], leading
111 to increased hospitalization time [4], clinical complications and mortality [5]. Furthermore,
112 CDI is associated with considerable healthcare expenditure, equating to \$1.5 billion annually
113 within the USA [6].

114

115 Recurrent CDI remains a major clinical challenge. A key clinical dilemma in the management
116 of CDI patients is prediction of the risk of recurrence caused by either re-exposure to *C.*
117 *difficile* or reactivation of dormant spores within vulnerable patients. The rate of recurrence
118 within eight weeks following treatment for a primary episode of CDI is 15-25%, and rises as
119 high as 40-60% for patients experiencing further recurrences [7,8]. Updated CDI clinical
120 guidelines recognise that the risk of recurrence in primary CDI patients may influence the
121 preferred management approach and the need for preventative strategies, such as the
122 potential benefit for bezlotoxumab in primary CDI patients with higher recurrence risk
123 compared to those with lower risk [9,10]. However, at present, limited tools exist for the
124 prediction of CDI recurrence [11], with risk of recurrence estimation based upon the use of
125 clinical criteria (including age, immunocompromise, and severity of CDI at diagnosis [9,12]).
126 The dynamic assessment of biomarkers could be important not only to stratify low- and
127 high-risk patients, but also to further understand the mechanisms underlying recurrence.

128

129 One such biological area of interest relates to the contribution of gut microbiota-bile acid
130 interactions to the pathogenesis of CDI [13]. Prior antibiotic exposure is well-established as
131 the major risk factor for CDI [14] and entails a loss of microbial community members
132 possessing bile-metabolising enzymes (including bile salt hydrolases (BSHs) and 7- α -
133 dehydroxylase) [15–18]. More specifically, the antibiotic-exposed gut develops enrichment
134 in primary bile acids (including taurocholic acid (TCA), a major pro-germinant trigger to *C.*
135 *difficile* [19]), and loss of secondary bile acids, that have established roles in restricting the
136 growth of *C. difficile* and its toxin activity [20,21] and in modulating regulatory T cell activity

Main Manuscript

137 [22]. In addition, CDI is also characterised by reduced activity in the farnesoid X receptor
138 (FXR)-fibroblast growth factor (FGF) axis, important for bile acid homeostasis [23]. Fecal bile
139 acid profiles have shown promise for differentiating non-CDI diarrhea from CDI-related
140 diarrhea [24].

141

142 Our recent analysis of clinical factors in a cohort of patients experiencing a first episode of
143 uncomplicated CDI, demonstrated that primary diagnosis of CDI via toxin enzyme
144 immunoassay (EIA) and treatment with metronidazole were both factors increasing the risk
145 of recurrence [25]. Extending upon this work, we here present an analysis of longitudinal
146 fecal bile acid dynamics after anti-CDI therapy cessation until recurrence or until 8 weeks
147 post-therapy of patients within this cohort, with the joint aims of better delineating
148 differences in microbiome-bile acid interactions in patients with primary CDI who recur or
149 not, and in identifying potential biomarkers that may predict future CDI recurrence.

150

151 **3. Methods:**

152 **3.1. Patient cohort:**

153 This cohort has been previously-described [25]. In brief, all participating patients were
154 recruited from the inpatient service at Brigham and Women's Hospital (BWH; Boston, USA)
155 as well as two surrounding community hospitals (Brigham and Women's Faulkner Hospital
156 and Newton Wellsley Hospital). Potentially eligible patients were identified by daily reports
157 of patients with positive stool tests for *C. difficile* provided by the BWH Clinical Microbiology
158 Laboratory. *C. difficile* infection was defined as the presence of diarrhea, positive laboratory
159 tests (i.e. glutamate dehydrogenase (GDH) and EIA toxin or polymerase chain reaction for
160 toxin B, depending upon the testing methods used at the associated hospital laboratory),
161 and clinician decision to treat the patient for CDI. Primary CDI was defined as no prior
162 episodes of CDI within the prior six months. Patients who were excluded were: patients with
163 inflammatory bowel disease; patients with inherited or acquired immunodeficiencies;
164 severe or fulminant CDI, as diagnosed by IDSA and/or ACG guidelines [9,10]; or the need for
165 ongoing non-CDI antibiotic use that continued past the CDI antibiotic course.

166

167 Participating patients were recruited at the time of CDI diagnosis and samples collected
168 through eight weeks post-completion of their anti-CDI therapy to assess for recurrence, with

Main Manuscript

169 clinical assessments regarding presence or absence of diarrhea occurring at each time point.
170 Active stool collection began one week after completing anti-CDI antibiotics; stool was
171 collected up to twice a week for the first two weeks post-therapy completion, and then
172 weekly through to week eight. Recurrence was suspected if participants developed diarrhea
173 (Bristol stool scale 6-7) and at least three bowel movements daily for three days; if these
174 criteria were met, stool was assayed for *C. difficile* via GDH/EIA, and patients were
175 considered to have had a recurrence if both assays were positive. While 75 patients were
176 part of the original clinical cohort [25], only 56 had provided post-treatment serial stool
177 samples, and hence the present study has an effective $n=56$. The Institutional Review Board
178 (IRB) of Brigham and Women's Hospital gave ethical approval for this work. In addition, a
179 UK National Research Ethics Center (13/LO/1867) also gave ethical approval for this.

180

181 **3.2. Bile acid profiling:**

182 Fecal samples were analysed using ultra-high performance liquid chromatography-mass
183 spectrometry (UHPLC-MS). The protocols used for fecal extract preparation [26] and spectra
184 acquisition [18,27] were as previously-described.

185

186 Fecal extracts were prepared by extracting from lyophilized dried fecal samples using a 2:1:1
187 (vol) mixture of water, acetonitrile and 2-propanol to 10mg/mL, via use of a Biospec bead
188 beater with 1.0mm Zirconia beads followed by centrifugation (16,000× g , 20min) and
189 filtering the supernatant through 0.45µm microcentrifuge filters (Costar, Corning). Pooled
190 study reference (SR) samples, used as quality control of the profiling data and to monitor
191 assay performance, were prepared using equal parts of the fecal filtrates. In addition, for
192 assessment of linearity of analyte response [28], a series of SR sample dilutions was created
193 by diluting with ice-cold LC-MS grade methanol to the concentrations of 100%, 80%, 60%,
194 40%, 20%, 10%, 1% and analyzed at the start and end of each set of sample analyses.

195

196 Study and pooled SR samples were prepared for the UHPLC-MS profiling by aliquoting 75 µL
197 of filtered fecal extracts onto a 96-well plate and adding 75 µL of LCMS grade water and 75
198 µL of internal standard (IS) solution, followed by the addition of 75 µL of water to each well
199 for study samples, and 75 µL of ice-cold LC-MS grade methanol to each well for study
200 samples. Samples were mixed for two minutes on a plate mixer (1400 rpm at 2-8 °C),

Main Manuscript

201 incubated at -20 °C for 4 hours, then mix briefly and centrifuged at 3486xg for 10 minutes at
202 4 °C. Aliquots of 125 µL of clear supernatants of each sample were carefully transferred to
203 an analytical 96-well plate that was heat sealed and placed into the autosampler maintained
204 at 4 °C for the analysis. Blank samples were prepared in the same way but with an empty
205 tube (i.e. processing neat extraction solution through all steps, including the filter, allowing
206 tracing back of contamination peaks if present).

207

208 ACQUITY UHPLC-MS (Waters Ltd., Elstree, UK) coupled to a Xevo G2-S Q-ToF mass
209 spectrometer with an electrospray ionization source operating in negative ion mode (ESI-)
210 (Waters, Manchester, UK) was used for bile acids profiling. LC separation was conducted on
211 a ACQUITY BEH C8 column (1.7 µm, 100 mm × 2.1 mm) maintained at 60 °C. A gradient was
212 applied consisting of 10:1 water:acetonitrile, 1 mM ammonium acetate, pH 4.15 (A) and 1:1
213 isopropanol: acetonitrile (B). Details of the linear gradient method 90% A to 65% are
214 described elsewhere [18]. Injection volume was of 5 µL.

215

216 Mass spectrometry parameters were as follows: capillary voltage was set at 1.5 kV, cone
217 voltage at 60 V, source temperature at 150 °C, desolvation temperature at 600 °C,
218 desolvation gas flow at 1000 L/h, and cone gas flow at 150 L/h. Masslynx software (Waters,
219 Manchester, U.K.) was used for data acquisition and visual inspection.

220

221 A total of 81 bile acid authentic chemical standards were used to help annotation of
222 endogenous bile acids in fecal samples. The standards were split into eight mixtures
223 prepared in 1:3 water: methanol mixture and analyzed in the beginning and the end of the
224 run. The standards were also spiked into pooled SR sample analyzed across the run. This
225 helped monitor any potential retention time shifts for each bile acid species and to
226 determine retention time windows (regions of interest) used as an input together with *m/z*
227 values for the targeted extraction and integration of annotated bile acids using peakPanther
228 package [27].

229

230 Waters .RAW LC-MS data files were converted to .mzML format using Proteowizard
231 msconvert [29], with removal of signals with less than 100 ion counts. A total of 81 bile acid
232 species were annotated using authentic reference standards to determine their retention

Main Manuscript

233 times and their relative abundance integrated with the R package, peakPanther [30]. To
234 adjust for spectra intensity decay along the run, each feature was divided by a LOWESS
235 curve fitted on the SR samples' intensity [31]. Features with a coefficient of variation greater
236 than 30% in normalised SR samples, with a Pearson correlation with dilution factor below
237 0.7 (estimated using a dilution series of pooled SR samples), or below LOD in more than 20%
238 of study samples were discarded. Drift-correction and feature filtering were performed with
239 the nPYc-Toolbox [32]. Features were log-transformed and zeros imputed using
240 impute.QRILC from the *imputeLCMD* R package. For statistical analyses, features were also
241 mean-centered.

242

243 **3.3. Bile salt hydrolase activity assays:**

244 A spectrophotometry-based assay was used to assess the activity of microbial bile salt
245 hydrolase (BSH) in a subset of stool samples from the cohort, as previously-described [26].

246

247 **3.4. Data analysis and statistics:**

248 Statistical analyses were performed in R. Principal component analysis (PCA) of the
249 processed UHPLC-MS bile acid profiling data was performed using the *ropIs* R package[33].
250 Bile acid longitudinal trajectories were fitted using mixed effects models with the R package
251 *nlme*, stratifying samples by recurrence, with time (transformed as square root of days for
252 ease of modelling and visualisation; **Supplementary Figure 1**) as a co-variate and subject as
253 random intercept and time slope effect. For each feature, log-likelihood ratio tests of nested
254 models were used to determine the addition of non-linear (squared and cubic) time terms.
255 Area under the curve (AUC) of subject-specific fitted bile acid trajectories up to the
256 maximum timepoint of recurrence was calculated with *pracma* function *trapz* and compared
257 across recurring and non-recurring patients using a Mann-Whitney test, with Benjamini-
258 Hochberg false discovery rate correction (FDR) for multiple testing applied. FDR-adjusted P-
259 values (P_{adj}) < 0.1, corresponding to a 10 % false discovery rate, were considered significant.

260

261 To assess if bile acids contributed to recurrence, a Bayesian method was used to jointly
262 model bile acid longitudinal changes with the hazard risk of recurrence using
263 *jointModelBayes* function in the *JMbayes* package [34] with default parameters. The joint
264 survival model included age, gender, previous antibiotics (yes/no), *C. difficile* antibiotic type

Main Manuscript

265 (vancomycin/metronidazole) and diagnostic test (immunoassay/PCR) as covariates. Mean
266 area under the receiver operating characteristic curve (AUROC) was calculated for each
267 feature with the rocJM method from JMBayes package, using 1,000 Monte Carlo
268 permutations of training sets randomly built with 80% of recurrers' and 80% of non-
269 recurrers' samples and the remaining 20% of samples as test set. Three sets of ROC curves
270 were built using only one, two or three first timepoints of longitudinal bile acid
271 measurements to predict recurrence within nine days post-treatment.

272

273 **4. Results:**

274 **4.1. Participant details:**

275 Key clinical details of the 56 included patients are presented in **Table 1**. No patients had
276 received treatment with ursodeoxycholic acid, and two patients were treated with bile acid
277 sequestrants (one with colestipol, one with cholestyramine). Out of the 56 patients, 20
278 (36%) developed recurrence, with 80% of recurrence occurring within the first nine days
279 post-antibiotic treatment.

280

281 **4.2. Timepoint since diagnosis and recurrence status influence fecal bile acid profile in**
282 **primary CDI:**

283 In total, 71 bile acids were detected and relatively quantified in the peakPanther dataset
284 (see **Supplementary Table 1** for full list of bile acids).

285

286 We first sought to explore the overall impact of recurrence status and post-treatment
287 sampling time upon fecal bile acid profiles; as such, sample profiles were first visualised
288 using multivariate statistical analysis. On principal component analysis (PCA) of the
289 annotated bile acid profiles of all included samples and time points ($n=273$), samples
290 clustered mostly according to timepoint of sampling and by recurrence status of the patient
291 (**Figure 1A**). Individual trajectories showed that patients who did not recur had more
292 pronounced dynamic changes in their fecal bile acid composition than those who recurred
293 (**Figure 1B**); this higher temporal variability in non-recurrers was reflected in the comparison
294 of mean Euclidean distance of within-individual longitudinal samples collected the first nine
295 days post-treatment, which showed a higher - but not significant - dissimilarity in bile acid
296 composition across time in non-recurrers (Wilcoxon $p = 0.13$; **Figure 1C**).

297

298 **4.3. Recovery of microbial bile acid metabolism and restoration of the pre-morbid bile**
299 **acid milieu occurs in primary CDI patients without recurrence:**

300 To explore the temporal changes in bile acid metabolism in patients recovering from
301 primary CDI – and how recurrence may impact upon this – we compared the longitudinal
302 trajectories (across days to weeks) of fecal bile acids for the 20 patients experiencing
303 recurrence *versus* those 36 with no recurrence (**Figure 2A, B and C**).

304

305 Of the identified/ annotated bile acids, 24 were found to have marked differences in
306 longitudinal trajectories, assessed via comparison of area under curve (AUC) of subject-
307 specific trajectories among recurrence vs no recurrence (**Figure 2C and Supplementary**
308 **Table 1**). Two of the fecal bile acids with the most marked difference in AUC between
309 recurrers and non-recurrers were the secondary bile acids DCA and LCA, with AUCs for both
310 significantly higher in the non-recurring patients (DCA: $P_{adj} = 2.3 \times 10^{-5}$; LCA: $P_{adj} = 4.1 \times 10^{-3}$,
311 Mann-Whitney with Benjamini-Hochberg FDR; **Figure 2A**). Other fecal bile acid AUCs that
312 strongly differentiated recurrence from non-recurrence (with larger AUC in non-recurrers)
313 were particularly notable for also being secondary bile acids, and particularly derivatives of
314 DCA and LCA. This included glycine-conjugated forms (glycoDCA and glycoLCA; $P_{adj} = 2.4 \times 10^{-5}$
315 and 6.6×10^{-3} respectively, Mann-Whitney with Benjamini-Hochberg FDR), as well as forms
316 presumably derived from microbial hydroxysteroid dehydrogenase (HSDH) activity: isoDCA
317 (5- β -Cholanic Acid-3- β , 12- α -diol; $P_{adj} = 2.3 \times 10^{-5}$), the 3 β -HSDH-derived epimer of DCA; 3-
318 oxoDCA (5- β -Cholanic Acid 12- α -ol-3-one; $P_{adj} = 7.3 \times 10^{-5}$), the 3 α -HSDH-mediated
319 dehydrogenation of DCA; and 12-ketoDCA (3- α -Hydroxy-12-ketolithocholic acid; $P_{adj} =$
320 7.3×10^{-5}), the 12 α -HSDH-mediated dehydrogenation of DCA. In contrast, participants
321 experiencing recurrence (relative to those with non-recurrence) had higher AUC levels of
322 primary bile acid derivatives, sulfated and/or amide-conjugated ursodeoxycholic acid
323 (UDCA), or those similar to the 5 β -cholanic acid (ursocholanic acid) skeleton from which all
324 bile acids are derived; this included glycoursocholanic acid ($P_{adj} = 2.5 \times 10^{-5}$), chenodeoxycholic
325 acid-3-sulfate ($P_{adj} = 0.027$), as well as a number of oxo-derivatives of cholic acid, i.e. 3,7,12-
326 dehydrocholic acid, 3- α -hydroxy-7,12-diketocholeic acid, and 12-dehydrocholic acid|7-
327 dehydrocholic acid ($P_{adj} = 6.7 \times 10^{-4}$, 2×10^{-3} and 0.012 respectively).

328

329 Microbial bile salt hydrolases (BSH) are widely-distributed amongst bacteria resident in the
330 gut, and their action (in removing the taurine or glycine groups of primary bile acids
331 secreted into the gut) is the key rate-limiting step for microbiota-mediated $7\alpha/\beta$ -
332 dehydroxylation within the gastrointestinal tract [35]. Predicted bile salt hydrolase gene
333 abundance has previously been demonstrated by our group to be reduced in stool in
334 patients with recurrent CDI compared to those with primary CDI or control patients [15];
335 however, no comparison of BSH dynamics between recurring vs. non-recurring primary CDI
336 patients has been described previously. As such, we undertook BSH activity assays on a
337 subset of primary CDI patients who experienced CDI recurrence ($n=9$) and those with non-
338 recurrence ($n=18$). BSH activity increased over time amongst patients who did not relapse
339 ($\beta= 0.056$; likelihood ratio test $p= 0.018$; **Figure 3A**), while not enough data points were
340 available to test changes in BSH activity over time in patients who relapsed. Comparison of
341 BSH activity in recurrers vs. non-recurrers showed no significant difference in activity one
342 day after antibiotic treatment cessation (Wilcoxon, $p= 0.83$), and a trend towards a lower
343 BSH activity in patients who recurred at the latest timepoints measured, corresponding to a
344 mean \pm SD of 8 ± 7 days for recurrers and 35 ± 5 days for non-recurrers (Wilcoxon, $p= 0.078$;
345 **Figure 3B**).

346

347 **4.4. Fecal bile acid profiles immediately following antibiotic treatment for primary CDI**
348 **are related to risk of recurrence, and may be a predictive tool for recurrence:**

349 Comparison of AUC under the longitudinal trajectories allowed us to evaluate the overall
350 recovery of bile acid species over a time interval, but it does not provide information on the
351 imminent effect bile acids have on the risk of recurrence at a discrete timepoint. More
352 specifically, it would be of clear clinical interest if it was feasible to use a 'snapshot' fecal bile
353 acid profile obtained soon after the end of antibiotic treatment for primary CDI and use this
354 to gain insight into future recurrence risk. As such, we sought to further investigate the
355 relationship of specific bile acids to recurrence risk, and whether they had potential utility in
356 use as a predictive marker of recurrence.

357

Main Manuscript

358 To explore the contribution of fecal bile acids to the risk of recurrence, we undertook a
359 Bayesian joint longitudinal and survival modelling approach [34] (**Figure 4A** and
360 **Supplementary Table 2**). We found 16 bile acids associated with increased risk of
361 recurrence, while 15 were associated with reduced risk. Particularly noteworthy was the
362 marked increased risk of recurrence associated with fecal ursocolanic acid ($p=0.006$),
363 together with its conjugated derivatives, glycoursocholic acid ($p<0.001$) and
364 tauroursocholic acid ($p=0.034$). In addition, UDCA and its sulfated and tauro-conjugated
365 forms were also positively associated with recurrence. Conversely, it was noteworthy that
366 those bile acids most strongly associated with a reduced risk of recurrence were
367 predominantly glycine-conjugated primary bile acids, DCA and LCA, with many of them also
368 sulfated (**Figure 4A**).

369

370 We next aimed to assess the model's performance in predicting recurrence in patients with
371 primary CDI using fecal bile acid profiles. Given the time frame at which recurrences occur
372 both within this study and in clinical practice more generally, we modelled prediction of
373 recurrence within the 9 first days post-treatment, focusing on using only the measurements
374 of post-treatment day 1, as it would be more translatable to clinical practice than
375 conducting daily fecal samplings and BA measurements (**Figure 4D**). Area under the receiver
376 operating characteristic curve (AUROC) showed good prediction of recurrers within 9 days
377 post-treatment by 5- α -cholanic acid-3, 6-dione (AUROC=0.81; **Figure 4D**). Four other fecal
378 bile acids were also identified to have AUROCs > 0.73 for prediction of recurrence (**Figure**
379 **4D**). When using two or three consecutive measurements, 5- α -cholanic acid-3, 6-dione
380 continued to be the best predictor of recurrence, but AUROC was slightly smaller (0.79 and
381 0.78, respectively) (**Figure 4B, 4C**), suggesting that measuring 5- α -cholanic acid-3, 6-dione
382 on the first day post-treatment might be sufficient to predict the risk of recurrence.

383

384 5. Discussion:

385 The body of evidence supporting a close interaction between perturbed gut microbiota-
386 mediated bile acid metabolism and risk of CDI has been growing over the past decade [13],
387 and particularly regarding the impact of enriched gut TCA and loss of gut secondary bile
388 acids (particularly DCA and LCA) that characterise the CDI gut upon the ability of *C. difficile*

Main Manuscript

389 to undergo germination, vegetative growth, and toxin activity. However, to date, relatively
390 limited data has been described on the degree to which this axis is perturbed in primary CDI
391 specifically, and – if so – whether it might be exploitable as a biomarker to predict
392 recurrence within this condition.

393

394 Previous work from our laboratories described enrichment in gut primary bile acids and loss
395 of secondary bile acids in patients with both primary and recurrent CDI, together with
396 reduced predicted stool *bsh* gene abundance in recurrent CDI compared to primary CDI or
397 controls; however, this was assessed only cross-sectionally rather than longitudinally [15].
398 One confounder in interpreting cross-sectional datasets in CDI (particularly primary CDI) is
399 that vancomycin (the major anti-CDI therapy that most participants are initially treated
400 with) has itself been associated with an altered gut microbiota profile, as well as by loss of
401 fecal secondary bile acids and enrichment in primary unconjugated bile acids [36,37]. These
402 data support and extend upon our previous results by demonstrating different dynamics of
403 BSH functionality in recurrers compared to non-recurrers, as does the associated recovery
404 of transition of primary to secondary bile acids and their derivatives (a further nuance in this
405 system relates to the recent demonstration that different BSHs, due to their different
406 substrate specificity, have different degrees of protective ability against CDI [38]). The
407 conventional clinical interpretation of recurrence after an episode of primary CDI is to view
408 this as a pathogen-derived event (e.g. related to re-exposure of a vulnerable host to *C.*
409 *difficile*), and to respond with escalated or alternative anti-*C. difficile*-focused therapies;
410 however, these data suggest that recurrence may alternatively be viewed as a failure of
411 sufficient recovery of gut microbiome bile-metabolising functionality, and suggest by
412 extension that targeted microbiome-focused therapies or bile acid co-treatments may have
413 a potential role in mitigating the risk of recurrence. Supportive of this view, albeit from the
414 context of recurrent rather than primary CDI, is the finding that a key mechanism underlying
415 the efficacy of fecal microbiota transplant (FMT) in recurrent CDI is through restoration of
416 microbial BSH functionality, and the associated restoration of a pre-morbid gut bile acid
417 profile [18,39,40]. Similarly, both a spore-based ‘microbiome therapeutic’ derived from
418 alcohol-shocked healthy donor stool and a live biotherapeutic product consisting of eight
419 *Clostridia* strains were both shown to rapidly and sustainably restore stool secondary bile
420 acids [41,42].

Main Manuscript

421

422 While much research to date on gut microbiome-bile acid interactions in the context of CDI
423 has focused on the microbial enzymes BSH and 7- α -dehydroxylase [13], our data also give
424 novel insight into disruption to complex additional interactions within this domain. For
425 example, ursocolanic acid (also known as 5- β -cholanic acid, the ‘skeleton’ from which
426 other bile acids are derived, lacking the characteristic bile acid hydroxyl groups at positions
427 3, 7 and 12) and its simple derivatives were demonstrated in both main models to be
428 associated with adverse outcomes (i.e. higher AUCs in recurrers vs non-recurrers in the
429 predicted individual longitudinal trajectories, and predictive of recurrence risk in the joint
430 longitudinal-survival model). As another example, bile acids with oxo-/keto- groups
431 appeared to associate with risk of recurrence across both models; this particularly applied to
432 3-oxo groups (presumably representing gut microbial 3 α -hydroxysteroid dehydrogenase
433 (HSDH) activity), with such bile acids more predictive of increased recurrence risk in the joint
434 longitudinal-survival model. Conversely, one particularly interesting finding relates to
435 isoDCA (5- β -cholanic acid-3- β , 12- α -diol), which was observed in both models to be
436 associated with non-recurrence; this bile acid is the 3- β -hydroxy epimer of DCA, with its
437 presence in stool likely resulting from metabolism of DCA first via bacterial 3 α -HSDHs to 3-
438 oxoDCA, before bacterial 3 β -HSDH epimerization. As such, this suggests a role for gut
439 microbial 3 β -HSDH activity as being overall associated with protection from recurrence.
440 This finding extends upon previous *in vitro* work demonstrating that a broad range of gut
441 microbial derived secondary bile acids (including iso- forms) inhibit different aspects of the
442 life cycle of *C. difficile* and its toxin activity [20]. The range of gut bacteria with 3 α -HSDH
443 functionality is focused around (but not based purely within) the class of *Clostridia*, and
444 includes a number of bacteria with other well-characterised bile-metabolising functionality,
445 e.g. *Clostridium scindens*, the archetypal bacterium recognised to possess 7- α -
446 dehydroxylation functionality [43]; bacteria with 3 β -HSDH functionality include
447 *Ruminococcus gnavus* [44]. This observation leads us to conclude that the presence/
448 recovery of even very particular microbial bile-metabolising functions within the gut
449 microbiota may be sufficient to profoundly affect clinical outcome. In particular, our data
450 allows us to propose that primary CDI patients may typically retain gut bacterial 3- α -HSDH
451 functionality, but only the additional presence of 3- β -HSDH functionality results in reduced

Main Manuscript

452 recurrence risk; the presence of such functionality may represent gut microbiome recovery,
453 and/or a gut environmental *milieu* supportive of activity of this enzyme (i.e. presence of
454 required NADP(H), and appropriate pH and redox status [45]). The relevance of 3 β -HSDH-
455 mediated biotransformations of secondary bile acids to human health has been of recently-
456 growing interest; one pertinent example of this is the recent demonstration that
457 isoallothocholic acid produced from this enzyme system by *Odoribacteriaceae* strains had
458 potent effects against the growth of *C. difficile* and other pathobionts [46]. Furthermore,
459 isoLCA has recently been described to suppress pro-inflammatory T_H17 cell differentiation,
460 and to be at reduced levels in patients with colitis (at least colitis caused by IBD) [47].

461

462 A further interesting observation relates to the presence of UDCA and its derivatives as
463 associating with increased risk of recurrence in the joint longitudinal model; this seems
464 initially counterintuitive, given the apparent benefits associated with the exogenous use of
465 UDCA in a rodent CDI model (albeit potentially more through their impact upon bile acid
466 receptor systems rather than via direct effects on the life cycle of *C. difficile* [48]). However,
467 a possible explanation may be related to the observation from our longitudinal model that
468 no bile acids with 7- α -hydroxyl groups had higher AUCs in patients experiencing recurrence
469 as compared to non-recrurers. From these data, we conclude that recovery over time of the
470 7- α -dehydroxylase-driven transition from primary to secondary bile acids is a bacterial
471 function that drives bile acid biotransformation in a way that reduces recurrence risk. By
472 possessing a 7 β group, UDCA is not readily acted upon by 7- α -dehydroxylase-producing
473 bacteria, and may undergo downstream metabolism via more unconventional routes [49]
474 such as isomerization back to 7 α and then 7 α -dehydroxylation, or direct 7 β -
475 dehydroxylation to LCA, that have less impact than immediate 7- α -dehydroxylation of
476 primary bile acids upon direct bile acid-*C. difficile* interactions.

477

478 Extending upon this recognition of the centrality of microbiome-bile interactions in CDI
479 outcomes - coupled with the current lack of clinical biomarkers to prognosticate recurrence
480 in primary CDI - we further explored whether stool bile acid signatures may have utility as a
481 predictive tool for recurrence of CDI. Work to date within this field is relatively limited,
482 although we previously demonstrated that stool bile acid profiles could differentiate

Main Manuscript

483 primary from recurrent CDI with 84.2% accuracy [15], and fecal LCA (combined with urinary
484 p-cresol sulfate) has been demonstrated to predict response to FMT for recurrent CDI with
485 100% accuracy [50]. Our data here identifies at least five stool bile acids whose day 1 post-
486 treatment measurement was enough to predict recurrence within 9 days with AUROC
487 ranging from 0.81 to 0.73. This level of accuracy is similar to a previous study that used 16S
488 rRNA gene sequencing of a single stool sample from each of 88 primary CDI patients to
489 derive a microbial signature 'risk index' to predict recurrence, where an AUROC of 0.78 for
490 prediction of recurrence was reported [51]. Collectively, data such as these suggest that
491 microbiome and metabolome profiling in primary CDI may hold promise as accurate
492 biologically-rationale biomarkers to predict recurrence. However, such studies would need
493 replication in larger cohorts before they could be considered for use within clinical practice,
494 and pragmatic aspects regarding use of such assays (i.e. time consuming multi-step aspect
495 of sample preparation and batch effects in mass spectrometry analysis) would also require
496 careful consideration. Regarding the actual bile acids that predicted recurrence, it was of
497 particular interest that an unusual 'allo' bile acid - 5- α -cholanolic acid-3, 6-dione - was the
498 most robust predictor of recurrence, especially since formation of allo bile acids is
499 recognised to be a function of the gut microbiome of particular mammals (including rabbits
500 and rates) but not of humans [52]; further work is needed to establish the potential
501 biological significance of this bile acid to this disease state.

502

503 In conclusion, our data demonstrate distinctive differential gut bile acid trajectories that
504 differentiate recurrence from non-recurrence in patients with primary CDI, and define the
505 degree to which different gut bile acids associate with recurrence risk. These data extend
506 upon existing knowledge regarding the influence of microbiome-mediated bile acid
507 metabolism pathways upon clinical outcomes in CDI. By extension, these data suggest a
508 clinical case for focus upon therapies targeted at recovery of microbiome-bile acid
509 interactions to potentially reduce the risk of recurrence after primary CDI, and a feasible
510 role for stool bile acids as novel, rationale biomarkers to predict CDI recurrence.

511

512 **Data availability:** The bile acid profiling data generated for this project is available on the
513 MetaboLights Repository, study number: MTBLS657. All data produced in the present study
514 are available upon reasonable request to the authors.

515

516

517 **Table Legends:**

518 **Table 1: Clinical details of study participants.**

519

520

521 **Figure Legends:**

522 **Figure 1: Initial multivariate statistical analysis of fecal bile acid profiles obtained from**
523 **patients with primary CDI.** Principal component analysis (PCA) of annotated bile acid
524 relative intensities for all included samples ($n=273$), as coloured by time point of collection
525 (A) or recurrence status (B). C) Average within-individual Euclidean distance of bile acid
526 composition across timepoints for participants with more than one sample collected up to
527 the first 9 days post-treatment ($n= 45$; 12 recurrers and 33 non-recurrers). p value was
528 calculated using Wilcoxon test.

529

530 **Figure 2: Longitudinal trajectories of fecal bile acids of primary CDI patients, comparing**
531 **those experiencing recurrence versus those with no recurrence.** As measured across days
532 to weeks following the end of initial antibiotic therapy. Longitudinal trajectories are
533 demonstrated for A) deoxycholic acid (DCA) and B) lithocholic acid (LCA); thick lines
534 correspond to the mean fit for recurrers and non-recurrers, while thinner lines are the fitted
535 individual trajectories, from which area under curve (AUC) was calculated. Dots correspond
536 to the \log_{10} -transformed and mean-centered BA relative quantification. C) AUC of subject-
537 specific trajectories ordered by increasing median in recurrers. P values were obtained using
538 a Wilcoxon test and were adjusted (P_{adj}) using the Benjamini-Hochberg method. Only
539 significant features ($P_{adj} < 0.1$) are shown.

540

541 **Figure 3: Comparative temporal dynamics of stool BSH activity changes in patients with**
542 **primary CDI experiencing recurrence versus those with no recurrence.** As assessed using
543 plate-based precipitation assay. A) Time course of stool BSH activity. B) Comparison of stool
544 BSH activity at one day post-treatment (left) and at the latest measured time point (right). P
545 values were generated using Wilcoxon test (recurrers: $n=9$; non-recurrers: $n=18$).

546

547 **Figure 4: The contribution of fecal bile acids to risk of recurrence in patients with primary**
548 **CDI, and their use as a predictive tool of recurrence.** As assessed at early time points after
549 completion of antibiotics as therapy for primary CDI. A) Bayesian joint longitudinal and
550 survival model; a positive regression coefficient means that an increase in this particular bile
551 acid will increase risk of recurrence, while a negative regression coefficient means that an
552 increase in this bile acid will lower the risk of recurrence. CI denotes credibility interval.
553 Longitudinal-survival model fitted to each bile acid was used to predict recurrence within 9
554 days post-CDI treatment using measurements at B) three timepoints; C) two time points; D)
555 one time point only. Predictions were made using 80% of the data as training set and the
556 other 20% as test set. Receiver operating characteristic plots show the mean of 1,000 Monte
557 Carlo permutations for each bile acid, and the mean AUROC value is indicated in parenthesis
558 in the figure legend.

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

Main Manuscript

579

580

581 **Table 1:**

| Variable Name | n = 56 |
|--|---------------|
| Age (Mean ± SD) | 57.7 ± 16.3 |
| Male N,% | 36 (64.3%) |
| Race N,% | |
| Black | 9 (16%) |
| White | 41 (73.2%) |
| BMI (Mean ± SD) | 28 ± 6.5 |
| Received Antibiotics prior to Diagnosis N,% | 40 (71.4%) |
| Prior PPI use N,% | 27 (48.2%) |
| History of Cirrhosis N,% | 3 (5.3%) |
| Dietary restrictions N,% | |
| No | 52 (92.8%) |
| Vegan | 1 (1.7%) |
| Vegetarian | 2 (3.5%) |
| Gluten Free | 2 (3.5%) |
| Lactose Free | 1 (1.7%) |
| Smoking status | |
| Never | 34 (60.7%) |
| Former | 20 (35.7%) |
| Current | 2 (3.6%) |
| Diagnosis of Irritable Bowel Syndrome N,% | 6 (10.7%) |
| Baseline diarrhea or constipation N,% | |
| No | 42 (75%) |
| Diarrhea | 6 (10.7%) |
| Constipation | 6 (10.7%) |
| Both | 2 (3.6%) |
| Baseline Bristol Score (Mean ± SD) | 3.2 ± 1.3 |
| Ursodeoxycholic acid Use N,% | 0 (0.0%) |
| Cholestyramine Use N,% | 1 (1.7%) |
| Colestipol Use N,% | 1 (1.7%) |
| CDI Treatment Regimen | |
| Metronidazole | 14 (25%) |
| Vancomycin | 42 (75%) |
| Other current antibiotics (not for <i>C. difficile</i>) | 0 (0%) |
| Test Used for Diagnosis N,% | |
| PCR | 22 (39.2%) |
| EIA Toxin | 34 (60.7%) |
| Baseline Lab Values (Mean ± SD) | |
| WBC | 9.8 ± 5.3 |
| Hct | 36.1 ± 5.6 |
| Plts | 237.6 ± 103.6 |
| ALT | 44.4 ± 91.6 |
| AST | 41.3 ± 89.2 |
| Alkaline Phosphatase | 81.9 ± 40.0 |
| T. Bilirubin | 0.6 ± 0.4 |
| BUN | 20.3 ± 23.3 |
| Cr | 1.9 ± 5.2 |
| PT | 22.8 ± 29.4 |

Main Manuscript

| | |
|-----|------------|
| INR | 1.3 ± 0.31 |
|-----|------------|

582

583

584 **References:**

- 585 [1] Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al. Trends in U.S.
586 Burden of *Clostridioides difficile* Infection and Outcomes. *N Engl J Med*
587 2020;382:1320–30. <https://doi.org/10.1056/nejmoa1910215>.
- 588 [2] Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O'Connor L, et al. Diverse
589 Sources of *C. difficile* Infection Identified on Whole-Genome Sequencing. *N Engl J*
590 *Med* 2013;369:1195–205. <https://doi.org/10.1056/nejmoa1216064>.
- 591 [3] Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al.
592 Multistate Point-Prevalence Survey of Health Care–Associated Infections. *N Engl J*
593 *Med* 2014;370:1198–208. <https://doi.org/10.1056/NEJMoa1306801>.
- 594 [4] Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang H-Y, et al.
595 Incidence and Outcomes Associated With *Clostridium difficile* Infections: A Systematic
596 Review and Meta-analysis. *JAMA Netw Open* 2020;3:e1917597–e1917597.
597 <https://doi.org/10.1001/JAMANETWORKOPEN.2019.17597>.
- 598 [5] Feuerstadt P, Das R, Brandt LJ. The Evolution of Urban *C. difficile* Infection (CDI): CDI
599 in 2009–2011 Is Less Severe and has Better Outcomes Than CDI in 2006–2008. *Am J*
600 *Gastroenterol* 2014;109:1265–76. <https://doi.org/10.1038/ajg.2014.167>.
- 601 [6] Leffler DA, Lamont JT. *Clostridium difficile* Infection. *N Engl J Med* 2015;372:1539–48.
602 <https://doi.org/10.1056/NEJMra1403772>.
- 603 [7] Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin
604 versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the
605 USA: A double-blind, non-inferiority, randomised controlled trial. *Lancet Infect Dis*
606 2012;12:281–9. [https://doi.org/10.1016/S1473-3099\(11\)70374-7](https://doi.org/10.1016/S1473-3099(11)70374-7).
- 607 [8] Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al.
608 Vancomycin, Metronidazole, or Tolevamer for *Clostridium difficile* Infection: Results
609 From Two Multinational, Randomized, Controlled Trials. *Clin Infect Dis* 2014;59:345–
610 54. <https://doi.org/10.1093/cid/ciu313>.
- 611 [9] Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al.
612 Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and

Main Manuscript

- 613 Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update
614 Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis
615 2021;73:e1029–44. <https://doi.org/10.1093/cid/ciab549>.
- 616 [10] Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG
617 Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile
618 Infections. Am J Gastroenterol 2021;116:1124–47.
619 <https://doi.org/10.14309/ajg.0000000000001278>.
- 620 [11] Cobo J, Merino E, Martínez C, Cózar-Llistó A, Shaw E, Marrodán T, et al. Prediction of
621 recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. Int J
622 Antimicrob Agents 2018;51:393–8.
623 <https://doi.org/10.1016/j.ijantimicag.2017.09.010>.
- 624 [12] D’Agostino RB, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for
625 recurrent clostridium difficile infection based on clinical factors. Clin Infect Dis
626 2014;58:1386–93. <https://doi.org/10.1093/cid/ciu107>.
- 627 [13] Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the
628 pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14.
629 <https://doi.org/10.1177/17562848211017725>.
- 630 [14] Martin JSH, Monaghan TM, Wilcox MH. Clostridium difficile infection: Epidemiology,
631 diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol
632 2016;13:206–16. <https://doi.org/10.1038/nrgastro.2016.25>.
- 633 [15] Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, et al. Recurrent
634 Clostridium difficile infection associates with distinct bile acid and microbiome
635 profiles. Aliment Pharmacol Ther 2016;43:1142–53.
636 <https://doi.org/10.1111/apt.13616>.
- 637 [16] Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gouberne A, et al. Precision
638 microbiome reconstitution restores bile acid mediated resistance to Clostridium
639 difficile. Nature 2014;517:205–8. <https://doi.org/10.1038/nature13828>.
- 640 [17] Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, et al.
641 Functional Intestinal Bile Acid 7 α -Dehydroxylation by Clostridium scindens Associated
642 with Protection from Clostridium difficile Infection in a Gnotobiotic Mouse Model.
643 Front Cell Infect Microbiol 2016;6:191. <https://doi.org/10.3389/fcimb.2016.00191>.
- 644 [18] Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, et al.

Main Manuscript

- 645 Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in
646 the treatment of recurrent *Clostridioides difficile* infection. *Gut* 2019;68:1791–800.
647 <https://doi.org/10.1136/gutjnl-2018-317842>.
- 648 [19] Sorg JA, Sonenshein AL. Bile Salts and Glycine as Cogerminants for *Clostridium difficile*
649 Spores. *J Bacteriol* 2008;190:2505–12. <https://doi.org/10.1128/JB.01765-07>.
- 650 [20] Thanissery R, Winston JA, Theriot CM. Inhibition of spore germination, growth, and
651 toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived
652 secondary bile acids. *Anaerobe* 2017;45:86–100.
653 <https://doi.org/10.1016/j.anaerobe.2017.03.004>.
- 654 [21] Tam J, Icho S, Utama E, Orrell KE, Gómez-Biagi RF, Theriot CM, et al. Intestinal bile
655 acids directly modulate the structure and function of *C. difficile* TcdB toxin. *Proc Natl*
656 *Acad Sci U S A* 2020;117:6792–800. <https://doi.org/10.1073/pnas.1916965117>.
- 657 [22] Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, et al. Microbial bile acid metabolites
658 modulate gut ROR γ + regulatory T cell homeostasis. *Nat* 2019 5777790 2019;577:410–
659 5. <https://doi.org/10.1038/s41586-019-1865-0>.
- 660 [23] Monaghan T, Mullish BH, Patterson J, Wong GKSK, Marchesi JR, Xu H, et al. Effective
661 fecal microbiota transplantation for recurrent *Clostridioides difficile* infection in
662 humans is associated with increased signalling in the bile acid-farnesoid X receptor-
663 fibroblast growth factor pathway. *Gut Microbes* 2019;10:1–7.
664 <https://doi.org/10.1080/19490976.2018.1506667>.
- 665 [24] Robinson JI, Weir WH, Crowley JR, Hink T, Reske KA, Kwon JH, et al. Metabolomic
666 networks connect host-microbiome processes to human *Clostridioides difficile*
667 infections. *J Clin Invest* 2019;129:3792–806. <https://doi.org/10.1172/JCI126905>.
- 668 [25] Allegretti JR, Marcus J, Storm M, Sitko J, Kennedy K, Gerber GK, et al. Clinical
669 Predictors of Recurrence After Primary *Clostridioides difficile* Infection: A Prospective
670 Cohort Study. *Dig Dis Sci* 2020;65:1761–6. [https://doi.org/10.1007/s10620-019-](https://doi.org/10.1007/s10620-019-05900-3)
671 [05900-3](https://doi.org/10.1007/s10620-019-05900-3).
- 672 [26] Mullish BH, Pechlivanis A, Barker GF, Thursz MR, Marchesi JR, McDonald JAK.
673 Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism
674 interactions in health and disease. *Methods* 2018;149:49–58.
675 <https://doi.org/10.1016/j.ymeth.2018.04.028>.
- 676 [27] Sarafian MH, Lewis MR, Pechlivanis A, Ralphs S, McPhail MJW, Patel VC, et al. Bile

Main Manuscript




- 677 Acid Profiling and Quantification in Biofluids Using Ultra-Performance Liquid
678 Chromatography Tandem Mass Spectrometry. *Anal Chem* 2015;87:9662–70.
679 <https://doi.org/10.1021/acs.analchem.5b01556>.
- 680 [28] Sands CJ, Gómez-Romero M, Correia G, Chekmeneva E, Camuzeaux S, Izzi-Engbeaya
681 C, et al. Representing the Metabolome with High Fidelity: Range and Response as
682 Quality Control Factors in LC-MS-Based Global Profiling. *Anal Chem* 2021;93:1924–33.
683 https://doi.org/10.1021/ACS.ANALCHEM.0C03848/ASSET/IMAGES/LARGE/AC0C03848_0005.JPEG.
- 684
685 [29] Chambers MC, MacLean B, Burke R, Amodei D, Ruderman DL, Neumann S, et al. A
686 cross-platform toolkit for mass spectrometry and proteomics. *Nat Biotechnol*
687 2012;30:918–20. <https://doi.org/10.1038/nbt.2377>.
- 688 [30] Wolfer AM, D S Correia G, Sands CJ, Camuzeaux S, Yuen AHY, Chekmeneva E, et al.
689 peakPanther, an R package for large-scale targeted extraction and integration of
690 annotated metabolic features in LC–MS profiling datasets. *Bioinformatics* 2021.
691 <https://doi.org/10.1093/BIOINFORMATICS/BTAB433>.
- 692 [31] Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-Mcintyre S, Anderson N, et al.
693 Procedures for large-scale metabolic profiling of serum and plasma using gas
694 chromatography and liquid chromatography coupled to mass spectrometry. *Nat*
695 *Protoc* 2011 67 2011;6:1060–83. <https://doi.org/10.1038/nprot.2011.335>.
- 696 [32] Sands CJ, Wolfer AM, Correia GDS, Sadawi N, Ahmed A, Jiménez B, et al. The nPYc-
697 Toolbox, a Python module for the pre-processing, quality-control and analysis of
698 metabolic profiling datasets. *Bioinformatics* 2019;35:5359–60.
699 <https://doi.org/10.1093/BIOINFORMATICS/BTZ566>.
- 700 [33] Thévenot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the Human Adult Urinary
701 Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a
702 Comprehensive Workflow for Univariate and OPLS Statistical Analyses. *J Proteome*
703 *Res* 2015;14:3322–35.
- 704 [34] Rizopoulos D. The R Package JMbayes for Fitting Joint Models for Longitudinal and
705 Time-to-Event Data Using MCMC. *J Stat Softw* 2016;72:1–46.
706 <https://doi.org/10.18637/JSS.V072.I07>.
- 707 [35] Jones B V, Begley M, Hill C, Gahan CGM, Marchesi JR. Functional and comparative
708 metagenomic analysis of bile salt hydrolase activity in the human gut microbiome.



Main Manuscript

- 709 Proc Natl Acad Sci U S A 2008;105:13580–5.
710 <https://doi.org/10.1073/pnas.0804437105>.
- 711 [36] Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, et al. Impact of oral
712 vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. *J Hepatol*
713 2014;60:824–31. <https://doi.org/10.1016/J.JHEP.2013.11.034>.
- 714 [37] Reijnders D, Goossens GH, Hermes GDA, Zoetendal EG, Dejong CHC, Blaak
715 Correspondence EE, et al. Clinical and Translational Report Effects of Gut Microbiota
716 Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized
717 Double-Blind Placebo-Controlled Trial *Cell Metabolism Clinical and Translational*
718 *Report Effects of Gut Microbiota Mani. Cell Metab* 2016;24:63–74.
719 <https://doi.org/10.1016/j.cmet.2016.06.016>.
- 720 [38] Foley MH, Walker ME, Stewart AK, O’Flaherty S, Gentry EC, Allen G, et al. Distinct bile
721 salt hydrolase substrate preferences dictate *C. difficile* pathogenesis. *BioRxiv*
722 2022:2022.03.24.485529. <https://doi.org/10.1101/2022.03.24.485529>.
- 723 [39] Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, et al.
724 Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation
725 Are Sufficient to Control *Clostridium difficile* Germination and Growth. *PLoS One*
726 2016;11:e0147210. <https://doi.org/10.1371/journal.pone.0147210>.
- 727 [40] Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, et al. Microbiota
728 transplantation restores normal fecal bile acid composition in recurrent *Clostridium*
729 *difficile* infection. *Am J Physiol Liver Physiol* 2014;306:G310–9.
730 <https://doi.org/10.1152/ajpgi.00282.2013>.
- 731 [41] Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, et al. SER-109, an Oral
732 Microbiome Therapy for Recurrent *Clostridioides difficile* Infection. *N Engl J Med*
733 2022;386:220–9. <https://doi.org/10.1056/nejmoa2106516>.
- 734 [42] Dsouza M, Menon R, Crossette E, Bhattarai SK, Schneider J, Kim Y-G, et al.
735 Colonization of the live biotherapeutic product VE303 and modulation of the
736 microbiota and metabolites in healthy volunteers. *Cell Host Microbe* 2022;30:583-
737 598.e8. <https://doi.org/10.1016/J.CHOM.2022.03.016>.
- 738 [43] Guzior D V., Quinn RA. Review: microbial transformations of human bile acids.
739 *Microbiome* 2021;9:1–13. <https://doi.org/10.1186/S40168-021-01101-1/FIGURES/5>.
- 740 [44] Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-


Main Manuscript



- 741 derived bile acids. *Nat Chem Biol* 2015 119 2015;11:685–90.
- 742 <https://doi.org/10.1038/nchembio.1864>.
- 743 [45] Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal
744 bacteria. *J Lipid Res* 2006;47:241–59. <https://doi.org/10.1194/jlr.R500013-JLR200>.
- 745 [46] Sato Y, Atarashi K, Plichta DR, Arai Y, Sasajima S, Kearney SM, et al. Novel bile acid
746 biosynthetic pathways are enriched in the microbiome of centenarians. *Nature*
747 2021;599:458–64. <https://doi.org/10.1038/s41586-021-03832-5>.
- 748 [47] Paik D, Yao L, Zhang Y, Bae S, D’Agostino GD, Zhang M, et al. Human gut bacteria
749 produce TH17-modulating bile acid metabolites. *Nat* 2022 2022:1–6.
750 <https://doi.org/10.1038/s41586-022-04480-z>.
- 751 [48] Winston JA, Rivera AJ, Cai J, Thanissery R, Montgomery SA, Patterson AD, et al.
752 Ursodeoxycholic acid (udca) mitigates the host inflammatory response during
753 *Clostridioides difficile* infection by altering gut bile acids. *Infect Immun* 2020;88.
754 <https://doi.org/10.1128/IAI.00045-20>.
- 755 [49] Doden HL, Ridlon JM. Microbial Hydroxysteroid Dehydrogenases: From Alpha to
756 Omega. *Microorg* 2021, Vol 9, Page 469 2021;9:469.
757 <https://doi.org/10.3390/MICROORGANISMS9030469>.
- 758 [50] Farowski F, Solbach P, Tsakmaklis A, Brodesser S, Cruz Aguilar MR, Cornely OA, et al.
759 Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent
760 *Clostridioides difficile* infection. *Dig Liver Dis* 2019;51:944–51.
761 <https://doi.org/10.1016/j.dld.2019.01.012>.
- 762 [51] Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, et al. Gut microbiome
763 predictors of treatment response and recurrence in primary *Clostridium difficile*
764 infection. *Aliment Pharmacol Ther* 2016;44:715–27.
765 <https://doi.org/10.1111/apt.13750>.
- 766 [52] Shiffka SJ, Kane MA, Swaan PW. Planar bile acids in health and disease. *Biochim*
767 *Biophys Acta - Biomembr* 2017;1859:2269–76.
768 <https://doi.org/10.1016/j.bbamem.2017.08.019>.
- 769


A**B****C**

A**B**



● Recruiter ● Non-recruiter

C

A**B**

A

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.08.22278181>; this version posted June 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

B**C****D**